Gilead Sciences (NASDAQ:GILD) Stock: Insider Wettan Keeley Cain Sells 3,399 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) EVP Wettan Keeley Cain sold 3,399 shares of the company’s stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $164.11, for a total value of $557,809.89. Following the sale, the executive vice president owned 5,360 shares in the company, valued at $879,629.60. The trade was a 38.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $170.87 on Wednesday. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a 12-month low of $116.88 and a 12-month high of $176.58. The business’s 50 day moving average is $154.00 and its 200-day moving average is $141.34.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same period last year, the business earned $2.47 earnings per share. The firm’s revenue was up 6.8% on a year-over-year basis. On average, equities research analysts predict that Gilead Sciences, Inc. will post -1.07 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. Gilead Sciences’s dividend payout ratio (DPR) is currently -103.80%.

Analyst Ratings Changes

A number of research analysts have recently commented on GILD shares. Barclays decreased their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Scotiabank upped their target price on shares of Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. UBS Group raised their target price on shares of Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Needham & Company LLC set a $175.00 price target on Gilead Sciences in a report on Friday, October 30th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $184.00 price target on shares of Gilead Sciences in a research report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $170.15.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Recent coverage highlights improving growth across Gilead’s business and strong recent results. Its latest reported quarter beat consensus on both earnings and revenue, with revenue up 6.8% year over year. This supports the positive investment case behind the stock’s advance toward a 52-week high. Article: Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
• Positive Sentiment: Analysts have recently raised price targets, including JPMorgan and Wells Fargo to $190, and maintained positive ratings—potential support for investor sentiment. Gilead Sciences analyst and stock information
• Neutral Sentiment: Gilead partner Xilio Therapeutics said it expects to deliver an option data package for its investigational cancer drug efarindodekin alfa to Gilead in the first half of 2027. Any value to Gilead depends on future data and potential payments; the update does not establish a near-term financial benefit. Xilio Therapeutics pipeline update
• Negative Sentiment: An executive vice president sold 3,399 shares, reducing his holdings by about 39%. The sale was made under a pre-arranged trading plan, which may limit its significance as a signal about the company’s outlook. Gilead Sciences insider-trading report
• Negative Sentiment: Vir, a competitor in hepatitis D, reported positive results for its experimental treatment. The news could raise competitive concerns, though the supplied report does not indicate an immediate impact on Gilead’s business. Vir rival advances hepatitis D treatment

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds have recently added to or reduced their stakes in GILD. PFS Partners LLC raised its position in shares of Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 96 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $25,000. Laurel Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth about $29,000. Kimelman & Baird LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter worth about $25,000. Finally, Toth Financial Advisory Corp boosted its holdings in shares of Gilead Sciences by 85.5% during the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.